cisplatin,pembrolizumab,gemcitabine,pemetrexed
merck
['keytruda', 'lcsm,(-blcsm)']
the 24-month event-free survival rate was 62.4% with keytruda plus chemotherapy and adjuvant keytruda compared with 40.6% for placebo plus chemotherapy. #asco23 #lcsm 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.